Molecular Tumor Board-Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial.
Rachel W MillerMegan Leigh HutchcraftHeidi L WeissJianrong WuChi WangJinpeng LiuRani JayswalMikayla BuchananAbigail AndersonDerek B AllisonRiham H El KhouliReema A PatelJohn L VillanoSusanne M ArnoldJill M KolesarPublished in: JCO precision oncology (2022)
When treated with MTB-directed therapy, most patients experienced improved PFS compared with immediately prior treatment. MTB-directed targeted therapy may be a strategy to improve outcomes for patients with advanced cancer.
Keyphrases
- advanced cancer
- palliative care
- phase ii
- clinical trial
- mycobacterium tuberculosis
- open label
- end stage renal disease
- newly diagnosed
- pulmonary tuberculosis
- ejection fraction
- chronic kidney disease
- healthcare
- type diabetes
- double blind
- study protocol
- randomized controlled trial
- mesenchymal stem cells
- stem cells
- patient reported outcomes
- weight loss
- quality improvement
- placebo controlled
- affordable care act
- skeletal muscle
- glycemic control
- smoking cessation